The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

EXCLUSIVE: New mum Zara was shattered when told she had bowel cancer, but a new drug trial at The Christie in Manchester has ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

A study led by UCLA has discovered that JAK inhibitors could potentially prevent or reverse immune-related diabetes triggered ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.